Bristol Myers Squibb Co: (NYSE: BMY)

$46.44

-0.36 (-0.77%)

Volume 9,460,342

Jun 17 04:01 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		46.13 - 47.08
	
		52wk Low - High
		30.64 - 49.57
	
		Previous Close
		46.80
	
		Avg. Volume
		12,413,057
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		76.87 B
	
		Div - Yield
		1.40 - 2.99
	
		Beta
		0.46
	
		P/E (F1)
		25.87
	
		Current Year Est.
		1.81
	
		Quarterly Earnings ESP 
		2.22%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		180 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/29/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            25.87
                        
                            PEG Ratio
                            5.64
                        
                            Current Year Est.
                            1.81
                        
                            Current Quarter Estimate
                            0.45
                        
                            Most Accurate Estimate
                            0.46
                        
                            Earnings ESP 
                            2.22%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            1.73
                        
                            Expected Earnings Growth
                            4.59%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.   
Full BMY Company Report

 Analyst Report on BMY

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
BMY Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.45	0.46	1.81	2.11
Number of Estimates	10	9	13	11
Low Estimate	0.43	0.43	1.78	1.93
High Estimate	0.47	0.48	1.85	NA
Year Ago EPS	0.48	0.37	1.99	1.81
EPS Growth	-6.87%	24.62%	-9.08%	16.57%

More BMY Estimates

Average Earnings Estimates for BMY

EPS Growth for BMY

Industry Analysis

Name	Symbol	Previous Close
BRISTOL-MYERS	BMY	46.80
NOVO-NORDISK AS	NVO	167.58
ABBOTT LABS	ABT	36.81
ABBVIE INC	ABBV	43.21
ALLERGAN INC	AGN	101.14
ASTRAZENECA PLC	AZN	50.80
BAYER A G -ADR	BAYRY	108.97
GLAXOSMITHKLINE	GSK	52.49
JOHNSON & JOHNS	JNJ	84.91
LILLY ELI & CO	LLY	52.05

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

Simcere Ties Up with Bristol-Myers

Jun 17, 2013

Data on BMY/ AbbVie's elotuzumab

Jun 17, 2013

Encouraging Data from Bristol-Myers

Jun 13, 2013

Priority Review for Gilead Drug

Jun 10, 2013

Priority Review for AZN/BMY Drug

Jun 06, 2013

Encouraging data from Bristol-Myers

Jun 05, 2013

The Medicines Co. Inks Deal with ProFibrix

Jun 05, 2013

Incyte Reveals Data on Oncology Candidate

Jun 04, 2013

More BMY Zacks Commentary

Financials

EPS TTM	1.73
Sales	17,621
Net Income	1,468
Price/Earnings	27.05
Price/Book	5.61
Price/Cash Flow	19.10
Price/Sales	4.74

More BMY Financials

News

AstraZeneca and Bristol-Myers Squibb Releases Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies - Close-Up Media

Jun 17, 2013

BMS and AstraZeneca's BLA for lipodystrophy drug receives FDA acceptance - Datamonitor

Jun 17, 2013

Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals - Pr Newswire

Jun 17, 2013

Pharma Stocks: Court Ruling`s Real Meaning - YCharts

Jun 17, 2013

Gilead`s Potential Megablockbuster Raises the Bar - TheMotleyFool

Jun 16, 2013

Beware the Bullishness on Bristol-Myers - TheMotleyFool

Jun 15, 2013

Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma - Businesswire

Jun 15, 2013

Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study - Benzinga

Jun 15, 2013

See All News Stories on BMY

Broker Recommendations

Current ABR	2.38
ABR (Last Week)	2.38
# of recs in ABR	21
Average Target Price	45.04
Industry Rank by ABR	180 out of 265
Rank in Industry	2 out of 15

More BMY Broker Recommendations

Day Low - High	46.13 - 47.08
52wk Low - High	30.64 - 49.57
Previous Close	46.80
Avg. Volume	12,413,057
Industry	LARGE CAP PHARMA
Market Cap	76.87 B
Div - Yield	1.40 - 2.99
Beta	0.46
P/E (F1)	25.87
Current Year Est.	1.81
Quarterly Earnings ESP	2.22%

P/E (F1)	25.87
PEG Ratio	5.64
Current Year Est.	1.81
Current Quarter Estimate	0.45
Most Accurate Estimate	0.46
Earnings ESP	2.22%
Next Earnings Report Date	07-24-2013
EPS Last Year	1.73
Expected Earnings Growth	4.59%

Username: Password:

Remember me [?]

Bristol Myers Squibb Co: (NYSE: BMY)

$46.44

-0.36 (-0.77%)

Volume 9,460,342

Jun 17 04:01 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations